Lec # | Topics |
---|---|
Part One: Foundations of Bio-Medical Ethics and Modern "Bio-Politics" | |
1 | Section One: Introduction: Bio-Medical Ethics and Bio-Politics: From Clinical Practice and Medical Research to Crisis of Medical Humanitarianism in the Field (PDF) |
2 | Section Two: Principles of Ethical Medical Practice and Research: Autonomy, Justice, Beneficence, and Nonmaleficience (PDF) What is Bio-Medical Ethics? |
3-4 | Section Three: Competing Discourses on Bioethics and Bio-Medical Practice - Anthropology, Feminism, Theology, and Law (PDF) |
5-7 | Section Four: The Creation of Doctors and the Clinical Gaze or "Whose Body Is It, Anyway?" (PDF 1) (PDF 2) (PDF 3) |
8-9 | Section Five: Ethical Issues in the Practice of Medicine: Confidentiality and Disclosure; Patient Autonomy and Informed Consent (PDF 1) (PDF 2) |
10-11 | Section Six: Dilemmas of Public Health Practice: The Limits of Resources and its Allocation (PDF 1) (PDF 2) |
Part Two: Medical Technologies, the Body and the State | |
12-13 | Section Seven: Medical Research and Ethical Medical Experimentation - from Eugenics to Anti-Retroviral Drug Trials (PDF 1) (PDF 2) |
14-15 | Section Eight: Race, Contraception and Family Planning: Contemporary Eugenics? (PDF 1) (PDF 2) |
Part Three: Globalizing Bioethics - The Politics of Reproduction | |
16-17 | Section Nine: The Politics of Gender, Reproductive Technologies and Family Planning across Cultures (PDF 1) (PDF 2) |
18 | Section Ten: Infertility, Assisted Reproduction, Kinship, and Citizenship across Cultures (PDF) |
19-20 | Section Eleven: State Politics of Human Genetic Engineering, Stem Cell Research, Cloning, and "Surplus Embryos" (PDF 1) (PDF 2) Lecture 20 Guest Speaker: Dr. James Sherley, MIT Assoc. Professor of Biological Engineering |
Part Four: Playing God? Life, Death, Bodies, and Spirits | |
21-24 | Section Twelve: Organ Transplantation, End of Life Issues, and Death across Cultures (PDF 1) (PDF 2) (PDF 3) (PDF 4) |
Part Five: Human Rights, Infectious Disease, and the Global Medical Commons | |
25-26 | Section Thirteen: Clinical Dilemmas, Public Health, and Global Pharmaceuticals (PDF 1) (PDF 2) |